ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
Non Small Cell Lung Carcinoma
DRUG: Gefitinib|DRUG: Carboplatin|DRUG: Paclitaxel|PROCEDURE: Radiation
To determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
To evaluate the activity potential of the combination of ZD1839, carboplatin, paclitaxel & radiation therapy|Estimating the objective response rate (complete response [CR] & partial response [PR]) as assessed by positron emission tomography with (18F)-labelled fluorodeoxyglucose (PET-FDG)|To estimate the objective response rate (CR and PR) as assessed by computerised tomography (CT) scan|To estimate the complete response rate (CR) as assessed by PET-FDG|To estimate progression free survival (PFS) as assessed by clinical examination, chest x-ray, CT scan ± PET-FDG|To estimate overall survival|To characterise the safety and tolerability of ZD1839 combined with concurrent carboplatin, paclitaxel and radiation|To determine the site of first failure (characterised as local-regional, distant or both)
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.